Not available
Quote | Bio-Rad Laboratories Inc. Class A (NYSE:BIO)
Last: | $278.785 |
---|---|
Change Percent: | -2.28% |
Open: | $283.79 |
Close: | $285.28 |
High: | $285.27 |
Low: | $277.36 |
Volume: | 137,125 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Bio-Rad Laboratories Inc. Class A (NYSE:BIO)
2024-04-23 06:58:24 ET More on Danaher Danaher: All In On Life Sciences, And Market Update Danaher Corporation (DHR) TD Cowen 44th Annual Health Care Conference (Transcript) Danaher: Better Positioned For The Future Danaher Non-GAAP EPS of $1.92 beats by $0.2...
2024-04-22 12:53:43 ET More on S&P 500 Index: Fed's Commercial Banking Report Shows Economic Headwinds, But Deposit Growth Bucks Trend S&P 500: Capitulation? Week Starting 22nd April (Technical Analysis) Powell Playing Games: 'Sell In May' Is Now 'Sell Before...
Message Board Posts | Bio-Rad Laboratories Inc. Class A (NYSE:BIO)
Subject | By | Source | When |
---|---|---|---|
Long and strong lets hope im right | SAE | investorshub | 05/02/2023 5:06:29 PM |
$BIO When is this gonna take off? | buhg1b | investorshub | 05/01/2023 2:34:39 AM |
$BIO Price gaining | SAE | investorshub | 04/30/2023 5:11:47 PM |
$BIO Price trading last up | PirateGary | investorshub | 04/30/2023 1:08:44 AM |
$BIO MomentumIts now | locksflooring | investorshub | 04/25/2023 2:33:56 AM |
News, Short Squeeze, Breakout and More Instantly...
Bio-Rad Laboratories Inc. Class A Company Name:
BIO Stock Symbol:
NYSE Market:
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conf...
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of ...